Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
128M
-
Number of holders
-
126
-
Total 13F shares, excl. options
-
76.2M
-
Shares change
-
-4.42M
-
Total reported value, excl. options
-
$425M
-
Value change
-
-$33.2M
-
Put/Call ratio
-
0.5
-
Number of buys
-
64
-
Number of sells
-
-38
-
Price
-
$5.58
Significant Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q2 2024
139 filings reported holding CTKB - Cytek Biosciences, Inc. - Common Stock - $0.001 par value as of Q2 2024.
Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) has 126 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 76.2M shares
of 128M outstanding shares and own 59.53% of the company stock.
Largest 10 shareholders include BlackRock Inc. (17.1M shares), VANGUARD GROUP INC (11.7M shares), BROWN CAPITAL MANAGEMENT LLC (11.4M shares), HHLR ADVISORS, LTD. (6.66M shares), STATE STREET CORP (3.97M shares), NEW YORK STATE COMMON RETIREMENT FUND (2.95M shares), GEODE CAPITAL MANAGEMENT, LLC (2.58M shares), WELLINGTON MANAGEMENT GROUP LLP (2.14M shares), DIMENSIONAL FUND ADVISORS LP (1.47M shares), and GOLDMAN SACHS GROUP INC (1.36M shares).
This table shows the top 126 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.